A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Glioblastoma (GBM) is a heterogeneous brain tumor entity from infancy through adulthood. ALK gene fusions enriched in congenital and infant GBM have emerged as druggable driver alterations. Understanding the molecular basis and prevalence of ALK gene rearrangements will help define patients with GBM who may benefit from ALK-targeted therapy. See related article by Blandin et al., p. xxx.

Keyphrases

advanced non small cell lung cancer
copy number
genome wide
genome wide identification
risk factors
depressive symptoms
epidermal growth factor receptor
cancer therapy
genome wide analysis
body mass index